Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.

Abstract:

:Oestrogen receptor (ER) levels are usually maintained on acquisition of tamoxifen resistance in the clinic, however, tumour re-growth is associated with increased expression of epidermal growth factor receptor (EGFR) and activation of the mitogen activated protein kinase (MAPK) pathway. In the present study we have used the ER down-regulator fulvestrant ('Faslodex') to investigate the influence of the ER on growth of a tamoxifen-resistant (TAM-R) human breast cancer cell line. Expression levels of ER mRNA and protein were equivalent in parental wild-type MCF-7 (WT) and TAM-R cells. Fulvestrant eliminated ER protein expression and inhibited proliferation in both cell lines. The growth inhibitory effects of fulvestrant were associated with a decrease in basal EGFR, c-erbB2 and ERK1/2 activity in TAM-R but not WT cells. ER functionality as determined by oestrogen response element (ERE)-luciferase reporter activity and expression of PgR, pS2 and transforming growth factor alpha (TGFalpha) was significantly reduced in TAM-R compared to WT cells and was further decreased by fulvestrant treatment in both cell lines. Epidermal growth factor (EGF) and TGFalpha significantly increased EGFR/MAPK pathway activity in both cell lines. Ligand-induced EGFR/MAPK activation promoted TAM-R cell growth in both the absence and presence of fulvestrant, whereas no proliferative activity was observed under the same conditions in WT cells. These results suggest that the ER modulates EGFR/MAPK signalling efficiency in TAM-R cells possibly through the regulation of TGFalpha availability. This effect may be overcome by the action of exogenous EGFR ligands, which strengthen EGFR/MAPK signalling activity to generate endocrine-insensitive cell growth.

authors

Hutcheson IR,Knowlden JM,Madden TA,Barrow D,Gee JM,Wakeling AE,Nicholson RI

doi

10.1023/A:1025484908380

subject

Has Abstract

pub_date

2003-09-01 00:00:00

pages

81-93

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

81

pub_type

杂志文章
  • Predictive value of lymphoscintigraphy in patients with breast cancer-related lymphedema undergoing complex decongestive therapy.

    abstract:PURPOSE:We evaluated the prognostic value of lymphoscintigraphy after complex decongestive therapy (CDT) in breast cancer-related secondary lymphedema. METHODS:Prior to CDT, 80 patients with breast cancer-related lymphedema underwent a 99mTc tin-colloid lymphoscintigram. We investigated the uptake patterns of axillary...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-5041-2

    authors: Kim YH,Hwang JH,Bae JH,Choi JY

    更新日期:2019-02-01 00:00:00

  • A two-stage approach to genetic risk assessment in primary care.

    abstract::Genetic risk prediction models such as BRCAPRO are used routinely in genetic counseling for identification of potential BRCA1 and BRCA2 mutation carriers. They require extensive information on the counselee and her family history, and thus are not practical for primary care. To address this gap, we develop and test a ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3686-2

    authors: Biswas S,Atienza P,Chipman J,Blackford AL,Arun B,Hughes K,Parmigiani G

    更新日期:2016-01-01 00:00:00

  • Sealing of postoperative axillary leakage after axillary lymphadenectomy using a fibrin glue coated collagen patch: a prospective randomised study.

    abstract::Seroma formation after axillary lymphadenectomy in women with breast cancer remains a problem despite many efforts to reduce surgery-related morbidity. In a prospective, randomised, open, parallel-group, controlled clinical trial we evaluated the effect of a fibrin-glue coated collagen patch (TachoComb H, Nycomed Phar...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1010671209279

    authors: Berger A,Tempfer C,Hartmann B,Kornprat P,Rossmann A,Neuwirth G,Tulusan A,Kubista E

    更新日期:2001-05-01 00:00:00

  • Distinct function of androgen receptor coactivator ARA70α and ARA70β in mammary gland development, and in breast cancer.

    abstract::Steroid receptor coactivators are important in regulating the function of the receptors in endocrine organ development and in cancers, including breast. Androgen receptor (AR) coactivator ARA70, was first identified as a gene fused to the ret oncogene and later characterized as an AR coactivator. We previously reporte...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1131-5

    authors: Wu X,Chen F,Sahin A,Albarracin C,Pei Z,Zou X,Singh B,Xu R,Daniels G,Li Y,Wei J,Blake M,Schneider RJ,Cowin P,Lee P

    更新日期:2011-07-01 00:00:00

  • High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.

    abstract:PURPOSE:Compared to breast cancer risk genes such as BRCA2, ATM, PALB2, and NBN, no defined phenotype is currently associated with biallelic pathogenic variants (PVs) in CHEK2. This study compared the prevalence of breast and other cancers in women with monoallelic and biallelic CHEK2 PVs. METHODS:CHEK2 PV carriers we...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05543-3

    authors: Rainville I,Hatcher S,Rosenthal E,Larson K,Bernhisel R,Meek S,Gorringe H,Mundt E,Manley S

    更新日期:2020-04-01 00:00:00

  • Racial differences in the familial aggregation of breast cancer and other female cancers.

    abstract::Although breast cancer familial aggregation has been studied in Caucasians, information for African-Americans is scant. We used family cancer history from the Women's Contraceptive and Reproductive Experiences study to assess the aggregation of breast and gynecological cancers in African-American and Caucasian familie...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-004-2046-9

    authors: Simon MS,Korczak JF,Yee CL,Daling JR,Malone KE,Bernstein L,Marchbanks PA,Folger SG,McDonald JA,Norman SA,Strom BL,Deapen D,Ursin G,Burkman RT,Press MF,Schwartz AG,Spirtas R

    更新日期:2005-02-01 00:00:00

  • GSTT1 and GSTP1 polymorphisms and breast cancer risk: a meta-analysis.

    abstract::Cytosolic glutathione S-transferase comprises multiple isoenzymes; studies have principally examined mu-1 (GSTM1: null/present), theta-1 (GSTT1: null/present) and pi-1 (GSTP1 Ile105Val) gene polymorphisms concerning breast cancer risk. Regarding GSTT1 and GSTP1 polymorphisms, studies remain controversial and no recent...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-009-0520-0

    authors: Sergentanis TN,Economopoulos KP

    更新日期:2010-05-01 00:00:00

  • Trajectories of quality of life following breast cancer diagnosis.

    abstract:PURPOSE:Although quality of life (QoL) improves over time for most breast cancer survivors (BCS), BCS may show different patterns of QoL. This study sought to identify distinct QoL trajectories among BCS and to examine characteristics associated with trajectory group membership. METHODS:BCS (N = 653) completed baselin...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4677-2

    authors: Goyal NG,Levine BJ,Van Zee KJ,Naftalis E,Avis NE

    更新日期:2018-05-01 00:00:00

  • Overview of luteinizing hormone-releasing hormone agonists in early breast cancer-benefits of reversible ovarian ablation.

    abstract::Goserelin ('Zoladex'), a luteinizing hormone-releasing hormone (LHRH) agonist induces reversible ovarian ablation in premenopausal women. It is the most extensively studied LHRH agonist for the treatment of breast cancer and data from a large clinical trial program show that, alone or in combination with tamoxifen, go...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/a:1020309715942

    authors: Jonat W

    更新日期:2002-10-01 00:00:00

  • Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy.

    abstract::We report a series of breast cancer patients with invasive skin and nail infections with Staphylococcus species that we attribute to the addition of pertuzumab to trastuzumab-based therapy. With the suspicion of an increased incidence of cutaneous infection in patients treated with pertuzumab and trastuzumab-based che...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-014-3190-5

    authors: Mortimer J,Jung J,Yuan Y,Kruper L,Stewart D,Chung S,Yu KW,Mendelsohn M,D'Apuzzo M,Tegtmeier B,Dadwal S

    更新日期:2014-12-01 00:00:00

  • Higher stromal expression of transforming growth factor-beta type II receptors is associated with poorer prognosis breast tumors.

    abstract::Transforming growth factor-beta (TGFB) is a potent inhibitor of normal epithelial cell proliferation, and may be one of the regulatory factors that are perturbed during tumor development. While many tumor cell lines no longer respond to the inhibitory effects of TGFB due to a reduction or absence of the type II recept...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1023918026437

    authors: Barlow J,Yandell D,Weaver D,Casey T,Plaut K

    更新日期:2003-05-01 00:00:00

  • Pre-operative progesterone benefits operable breast cancer patients by modulating surgical stress.

    abstract:PURPOSE:We have reported a survival benefit of single injection of hydroxyprogesterone prior to surgery for primary tumour in patients with node-positive operable breast cancer. Hydroxyprogesterone was meant to recapitulate the luteal phase of menstrual cycle in these women. We wanted to understand the molecular basis ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4749-3

    authors: Chatterjee S,Chaubal R,Maitra A,Gardi N,Dutt A,Gupta S,Badwe RA,Majumder PP,Pandey P

    更新日期:2018-07-01 00:00:00

  • Breast-conserving surgery without axillary lymph node surgery or radiotherapy is safe for HER2-positive and triple negative breast cancer patients over 70 years of age.

    abstract:PURPOSE:The prognosis of elderly patients with hormone receptor-positive breast cancer is very good, and their survival is unaffected by performing breast-conserving surgery (BCS) without radiotherapy. Therefore, we aimed to verify that BCS without axillary lymph node dissection, sentinel lymph node biopsy, or radiothe...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05686-3

    authors: Zhong Y,Xu Y,Zhou Y,Mao F,Lin Y,Guan J,Shen S,Pan B,Wang C,Peng L,Huang X,Li Y,Wang X,Sun Q

    更新日期:2020-07-01 00:00:00

  • Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands.

    abstract:PURPOSE:A considerable part of ductal carcinoma in situ (DCIS) lesions may never progress into invasive breast cancer. However, standard treatment consists of surgical excision. Trials aim to identify a subgroup of low-risk DCIS patients that can safely forgo surgical treatment based on histologic grade, which highligh...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-05082-y

    authors: van Dooijeweert C,van Diest PJ,Willems SM,Kuijpers CCHJ,Overbeek LIH,Deckers IAG

    更新日期:2019-04-01 00:00:00

  • Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior.

    abstract:BACKGROUND:Epithelial-to-mesenchymal transition (EMT) has been implicated as an important step in the development of distant metastases. We therefore wished to study EMT status of primary breast carcinomas from patients who during follow-up developed distant metastases. METHODS:mRNA expression profiles of primary brea...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-05089-5

    authors: Savci-Heijink CD,Halfwerk H,Hooijer GKJ,Koster J,Horlings HM,Meijer SL,van de Vijver MJ

    更新日期:2019-04-01 00:00:00

  • Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study.

    abstract::The objective of this study was to determine the conversion rate of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER) and progesterone receptor (PR) between primary tumors and metastatic lesions in advanced breast cancer. Patients with suspected diagnosis of locally recurrent or metastatic breast...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s10549-013-2825-2

    authors: de Dueñas EM,Hernández AL,Zotano AG,Carrión RM,López-Muñiz JI,Novoa SA,Rodríguez AL,Fidalgo JA,Lozano JF,Gasión OB,Carrascal EC,Capilla AH,López-Barajas IB,Mateu MM,de Ceballos Reyna MH,Ferrando AO,Jañez NM,Ballerini VC

    更新日期:2014-02-01 00:00:00

  • HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites.

    abstract:BACKGROUND:Several recent epidemiologic studies examined the association between breast cancer risk and an inherited, single-nucleotide polymorphism in the HER2 gene, codon 655 G to A, which leads to an amino acid substitution of Ile to Val. Results of previous studies have been mixed, with most studies showing no asso...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1024068525763

    authors: Millikan R,Eaton A,Worley K,Biscocho L,Hodgson E,Huang WY,Geradts J,Iacocca M,Cowan D,Conway K,Dressler L

    更新日期:2003-06-01 00:00:00

  • Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.

    abstract::Germline mutations in the BRCA1/2 genes account for the majority of hereditary breast ovarian cancer (HBOC). Identification of causal mutations may have significant impact on clinical management of such families. Despite high mutation detection rate, many HBOC cases remain without identified cause. These cases warrant...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1325-x

    authors: Konecny M,Milly M,Zavodna K,Weismanova E,Gregorova J,Mlkva I,Ilencikova D,Kausitz J,Bartosova Z

    更新日期:2011-02-01 00:00:00

  • Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.

    abstract::NSABP B-43 is the first prospective, randomized phase III multi-institution clinical trial targeting high-risk, HER2-positive DCIS. It compares whole breast irradiation alone with WBI given concurrently with trastuzumab in women with HER2-positive DCIS treated by lumpectomy. The primary aim is to determine if trastuzu...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-013-2755-z

    authors: Siziopikou KP,Anderson SJ,Cobleigh MA,Julian TB,Arthur DW,Zheng P,Mamounas EP,Pajon ER,Behrens RJ,Eakle JF,Leasure NC,Atkins JN,Polikoff JA,Seay TE,McCaskill-Stevens WJ,Rabinovitch R,Costantino JP,Wolmark N

    更新日期:2013-11-01 00:00:00

  • Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.

    abstract:PURPOSE:The present study evaluated whether morphological-measured stromal and intra-tumour tumour-infiltrating lymphocytes (TILs) levels were associated with gene expression profiles, and whether TILs-associated genomic signature (GS) could be used to predict clinical outcomes and response to therapies in several brea...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4502-3

    authors: Kochi M,Iwamoto T,Niikura N,Bianchini G,Masuda S,Mizoo T,Nogami T,Shien T,Motoki T,Taira N,Tokuda Y,Doihara H,Matsuoka J,Fujiwara T

    更新日期:2018-01-01 00:00:00

  • Protein S and protein C level changes with adjuvant tamoxifen therapy in postmenopausal women.

    abstract::Tamoxifen citrate is a synthetic antiestrogen that provides survival benefit when given as adjuvant treatment in postmenopausal women with breast cancer. Venous thrombophlebitis may complicate tamoxifen treatment at a rate of approximately one per 800 treatment-years. To explore the possible procoagulant effects assoc...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00665973

    authors: Mamby CC,Love RR,Feyzi JM

    更新日期:1994-01-01 00:00:00

  • Sentinel node identification rate, but not accuracy, is significantly decreased after pre-operative chemotherapy in axillary node-positive breast cancer patients.

    abstract:BACKGROUND:The aim was to prove the low identification rate of sentinel lymph node biopsy (SNB) and to determine the feasibility of replacing axillary lymph node dissection (AND) in axillary lymph node positive patients after chemotherapy. METHODS:From October 2001 to July 2005, 875 consecutive patients with primary o...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-006-9330-9

    authors: Lee S,Kim EY,Kang SH,Kim SW,Kim SK,Kang KW,Kwon Y,Shin KH,Kang HS,Ro J,Lee ES

    更新日期:2007-05-01 00:00:00

  • Outcomes of a weight loss intervention among rural breast cancer survivors.

    abstract::Obese breast cancer survivors have increased risk of recurrence and death compared to their normal weight counterparts. Rural women have significantly higher obesity rates, thus weight control intervention may be a key strategy for prevention of breast cancer recurrence in this population. This one-arm treatment study...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s10549-011-1922-3

    authors: Befort CA,Klemp JR,Austin HL,Perri MG,Schmitz KH,Sullivan DK,Fabian CJ

    更新日期:2012-04-01 00:00:00

  • Association between financial burden and adjuvant hormonal therapy adherence and persistent use for privately insured women aged 18-64 years in BCBS of Texas.

    abstract:PURPOSE:The objective of this study is to understand an impact of financial burden on the adjuvant hormonal therapy (AHT) adherence and persistence for insured women aged 18-64 with early breast cancer in Texas. METHODS:We conducted a retrospective cohort study using claims data for population insured by Blue Cross Bl...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4704-3

    authors: Kim J,Rajan SS,Du XL,Franzini L,Giordano SH,Morgan RO

    更新日期:2018-06-01 00:00:00

  • Inhibitory effects of Indole-3-carbinol on invasion and migration in human breast cancer cells.

    abstract::Indole-3-carbinol (I3C) is a promising phytochemical agent in chemoprevention of breast cancer. Our present study is the first description of I3C that significantly inhibits the cell adhesion, spreading and invasion associated with an up-regulation of PTEN (a tumor suppressor gene) and E-cadherin (a regulator of cell-...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006495824158

    authors: Meng Q,Goldberg ID,Rosen EM,Fan S

    更新日期:2000-09-01 00:00:00

  • Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome.

    abstract:BACKGROUND:We report a novel BRCA1 LGR, involving the complete duplication of exon 3, in an Italian patient with a strong family history of breast and ovarian cancer. Our purpose is to provide an effective characterization of this LGR using a combination of different methods able to establish the exact breakpoints of t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4275-8

    authors: Concolino P,Rizza R,Hackmann K,Paris I,Minucci A,De Paolis E,Scambia G,Zuppi C,Schrock E,Capoluongo E

    更新日期:2017-07-01 00:00:00

  • The influence of clinical information on the accuracy of diagnostic mammography.

    abstract:OBJECTIVE:This study examined the influence of knowledge of clinical information on the accuracy of mammography in women referred for investigation of breast symptoms. METHODS:Subjects were sampled from all women consecutively attending a symptomatic breast clinic and aged 25-55 years. This included all 240 women show...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/B:BREA.0000025416.66632.84

    authors: Houssami N,Irwig L,Simpson JM,McKessar M,Blome S,Noakes J

    更新日期:2004-06-01 00:00:00

  • Digital compared to screen-film mammography: breast cancer prognostic features in an organized screening program.

    abstract::Our previous study found cancer detection rates were equivalent for direct radiography compared to screen-film mammography, while rates for computed radiography were significantly lower. This study compares prognostic features of invasive breast cancers by type of mammography. Approved by the University of Toronto Res...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3088-2

    authors: Prummel MV,Done SJ,Muradali D,Majpruz V,Brown P,Jiang H,Shumak RS,Yaffe MJ,Holloway CM,Chiarelli AM

    更新日期:2014-09-01 00:00:00

  • Loss of BRCA1 expression in sporadic male breast carcinoma.

    abstract::BRCA1 protein is normally expressed in the nuclei of breast epithelial cells and functions as a negative regulator of the cell cycle. Mutations of BRCA1 gene have been associated with familial breast carcinomas. Although somatic mutations have not been demonstrated in sporadic breast carcinomas, loss of nuclear expres...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1013317909431

    authors: Sun X,Gong Y,Rao MS,Badve S

    更新日期:2002-01-01 00:00:00

  • FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer.

    abstract:PURPOSE:Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer and associated with early metastasis, drug resistance, and poor patient survival. Fork head box M1 (FOXM1) is considered as an emerging molecular target due to its oncogenic role and high overexpression profile in 85% in TNBC. However, ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4207-7

    authors: Hamurcu Z,Kahraman N,Ashour A,Ozpolat B

    更新日期:2017-06-01 00:00:00